نتایج جستجو برای: betaferon

تعداد نتایج: 63  

Journal: :Acta medica Iranica 2010
Mehrdokht Mazdeh Saeed Afzali Mahmood Reza Jaafari

We aimed to compare the therapeutic effect of Avonex (Av), Betaferon (Be) & Rebif (Re) on the Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS). Ninety patients referring to Farshchian Hospital were entered in this study. The patients were divided into three equal groups: group 1 received Av, group 2 received Re and group 3 received Be, and after 24 months, comparison was done ...

Journal: :acta medica iranica 0
keivan basiri neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. masood etemadifar neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. fatemeh derakhshan neuroscience research center, isfahan university of medical sciences, isfahan, iran. fereshteh ashtari neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. vahid shaygannejad neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. zahra fatehi neuroscience research center, isfahan university of medical sciences, isfahan, iran.

none of the approved immunomodulatory drugs in adults multiple sclerosis (ms) patients have been officially approved for the pediatric patients and are currently used off-label in this population. in this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (avonex®) and subcutaneously injected interferon beta1-b (betaferon®) in children with definite relap...

2014
Sreeram Ramagopalan Radek Wasiak Andrew P. Cox Michael Hutchinson Bruce Taylor

BACKGROUND Multiple sclerosis (MS) is a common complex disorder, with new treatment options emerging each year. Social media is being increasingly used to investigate opinions about drugs, diseases and procedures. In this descriptive exploratory study, we sought to investigate opinions about currently available MS treatments. METHODS The Twitter resource Topsy was searched for tweets mentioni...

Journal: :iranian journal of neurology 0
ali imani department of health services management, school of management and medical information, tabriz university of medical sciences, tabriz, iran. mina golestani department of health services management, school of management and medical information, tabriz university of medical sciences, tabriz, iran

background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...

Journal: :Pharmacological reports : PR 2008
Arleta Matschay Elzbieta Nowakowska Hanka Hertmanowska Krzysztof Kus Anna Czubak

Multiple sclerosis (MS) is a neurological disease of the central nervous system in which dissipated demyelination lesions develop. The currently available pharmacotherapy and rehabilitation for this disease aims to preserve the patients' physical abilities and prevent disease progression and nervous system damage. The study evaluated the direct and indirect costs associated with two different t...

Journal: طب جانباز 2023

Multiple sclerosis (MS) is a chronic demyelinating disease which is considered to be an autoimmune disease impacting the central nervous system (CNS). Patients with MS may have certain orofacial manifestations and oral microbiological changes as a result of different treatment modalities. Thus, this study aimed to investigate the changes of Candida Albicans in normal oral flora during different...

2008

Background information Currently three interferon (IFN) beta preparations are registered for the treatment of certain stages of multiple sclerosis (MS). Two preparations (Rebif and Avonex) are produced from mammalian cells (CHO) and one preparation (Betaferon) from bacteria (E. coli). The two CHO-derived beta interferons are glycosylated products. The E. coli derived product, which is not glyco...

Journal: :Archives of neurology 2007
Frederik Barkhof Chris H Polman Ernst-Wilhelm Radue Ludwig Kappos Mark S Freedman Gilles Edan Hans-Peter Hartung David H Miller Xavier Montalbán Peter Poppe Marlieke de Vos Fatiha Lasri Lars Bauer Susanne Dahms Klaus Wagner Christoph Pohl Rupert Sandbrink

BACKGROUND In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic resonance imaging (MRI) lesions. OBJECTIVE To examine detailed MRI findings from the first 2 years of this trial. DESIGN Double-bli...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید